- Q3 2021 Chugai Pharmaceutical Co Ltd Earnings Call TranscriptOct 22, 2021円3841 (-0.93%)Earnings
- Chugai Pharmaceutical Co Ltd Information Meeting on RONAPREVE TranscriptAug 26, 2021
- Q2 2021 Chugai Pharmaceutical Co Ltd Earnings Call TranscriptJul 26, 2021円4176 (+1.19%)Earnings
- Chugai Pharmaceutical Co Ltd Information Meeting on Polivy TranscriptJun 03, 2021
- Q1 2021 Chugai Pharmaceutical Co Ltd Earnings Call TranscriptApr 22, 2021円4388 (+3.74%)Earnings
- Full Year 2020 Chugai Pharmaceutical Co Ltd Earnings Presentation TranscriptFeb 04, 2021
- Chugai Pharmaceutical Co Ltd Digital Strategy Meeting TranscriptDec 02, 2020
- Q3 2020 Chugai Pharmaceutical Co Ltd Earnings Call TranscriptOct 22, 2020円4156 (-3.46%)Earnings
- Chugai Pharmaceutical Co Ltd ESG Presentation TranscriptSep 29, 2020
- Chugai Pharmaceutical Co Ltd Information Meeting on ENSPRYNG Subcutaneous Injection TranscriptSep 14, 2020
- Q2 2020 Chugai Pharmaceutical Co Ltd Earnings Call TranscriptJul 27, 2020円5095 (-1.96%)Earnings
- Q1 2020 Chugai Pharmaceutical Co Ltd Earnings Call TranscriptApr 23, 2020円4410 (-0.38%)Earnings
- Full Year 2019 Chugai Pharmaceutical Co Ltd Earnings Presentation TranscriptJan 31, 2020
- Chugai Pharmaceutical Co Ltd Antibody Engineering Technologies Information Meeting TranscriptDec 09, 2019
- Q3 2019 Chugai Pharmaceutical Co Ltd Earnings Call TranscriptOct 24, 2019円2830 (+1.07%)Earnings
- Chugai Pharmaceutical Co Ltd Information Meeting on Rozlytrek TranscriptSep 05, 2019
- Q2 2019 Chugai Pharmaceutical Co Ltd Earnings Presentation TranscriptJul 26, 2019
- Chugai Pharmaceutical Co Ltd FoundationOne CDx Information Meeting TranscriptJul 04, 2019
- Chugai Pharmaceutical Co Ltd ESG Presentation TranscriptJun 18, 2019
- Q1 2019 Chugai Pharmaceutical Co Ltd Earnings Call TranscriptApr 24, 2019円2293.33 (+0.44%)Earnings
Chugai Pharmaceutical Co Ltd Information Meeting on Polivy Transcript
I am Takaki Koga, Polivy Lifecycle Leader at Chugai Pharmaceutical Company. Today, I will give you an overview of what Polivy is and then ask Dr. Izutsu to make his presentation.
The name of the product is Polivy Intravenous Infusion, 30 milligram or 140 milligrams, and the generic name is polatuzumab vedotin, genetical recombination. It's indications are relapsed or refractory diffuse large B-cell lymphoma, but the name of the disease is a bit long. And so I'd like to use the English abbreviation, DLBCL. The name Polivy has been coined with Po coming from its generic name, polatuzumab vedotin, liv standing for life and y derived from the symbol for an antibody as it is an antibody drug conjugate. Thus, its English name is Polivy and Japanese name, Polivy.
On development history, in overseas, development was started by Roche in 2011. In Japan, a Phase I study was started in 2014. And in the same year in overseas, a global Phase Ib/II study was started for second-line treatment of patients with relapsed or refractory follicular lymphoma, which includes those with DLBCL. This study
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)